Dashboard
Manage Tickers

BOLTBolt Biotherapeutics, Inc.

Nasdaq boltbio.com


$ 0.80 $ -0.03 (-3.9 %)    

Friday, 17-May-2024 15:58:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 0.7929
$ 0.83
$ 0.00 x 0
$ 0.00 x 0
$ 0.79 - $ 0.84
$ 0.79 - $ 2.03
592,892
na
30.18M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

leerink-partners-downgrades-bolt-biotherapeutics-to-market-perform-lowers-price-target-to-1
Leerink Partners Downgrades Bolt Biotherap...
05/15/2024 17:28:22

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 16:31:58

jones-trading-downgrades-bolt-biotherapeutics-to-hold
Jones Trading Downgrades Bolt Biotherapeut...
05/15/2024 16:11:32

Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold.

hc-wainwright--co-downgrades-bolt-biotherapeutics-to-neutral
HC Wainwright & Co. Downgrades Bolt Biothe...
05/15/2024 16:05:36

HC Wainwright & Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.

this-accenture-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-today
This Accenture Analyst Is No Longer Bullis...
05/15/2024 12:24:23

why-arcutis-biotherapeutics-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket
Why Arcutis Biotherapeutics Shares Are Tra...
05/15/2024 12:14:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 12:06:56

guggenheim-downgrades-bolt-biotherapeutics-to-neutral
Guggenheim Downgrades Bolt Biotherapeutics...
05/15/2024 10:27:58

Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.

stifel-downgrades-bolt-biotherapeutics-to-hold-lowers-price-target-to-15
Stifel Downgrades Bolt Biotherapeutics to ...
05/15/2024 09:39:58

Stifel analyst Stephen Willey downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold and lowers the price target fro...

bolt-biotherapeutics-q1-2024-gaap-eps-028-beats-049-estimate-sales-530m-beat-206m-estimate
Bolt Biotherapeutics Q1 2024 GAAP EPS $(0....
05/14/2024 20:31:53

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/03/2024 20:31:20

hc-wainwright--co-maintains-buy-on-bolt-biotherapeutics-maintains-8-price-target
HC Wainwright & Co. Maintains Buy on Bolt ...
03/22/2024 15:00:18

HC Wainwright & Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price ...

bolt-biotherapeutics-q4-eps-047-beats-048-estimate-sales-209m-beat-171m-estimate
Bolt Biotherapeutics Q4 EPS $(0.47) Beats ...
03/21/2024 20:20:10

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertu
Bolt Biotherapeutics Enrolls First Patient...
12/05/2023 12:02:08

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the t...

bolt-biotherapeutics-q3-eps-043-beats-050-estimate-sales-253m-beat-172m-estimate
Bolt Biotherapeutics Q3 EPS $(0.43) Beats ...
11/09/2023 22:23:19

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

bolt-biotherapeutics-presents-updated-clinical-data-from-phase-1-dose-escalation-trial-of-bdc-1001-as-monotherapy-and-in-combination-with-nivolumab-in-her2-expressing-tumors-at-esmo-2023-congress
Bolt Biotherapeutics Presents Updated Clin...
10/23/2023 14:32:49

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one pa...

bolt-biotherapeutics-announces-first-patient-dosed-in-phase-12-study-of-bdc-3042-in-patients-with-advanced-cancers
Bolt Biotherapeutics Announces First Patie...
10/17/2023 11:04:22

bolt-biotherapeutics-announced-that-updated-clinical-data-from-its-phase-12-dose-escalation-study-of-bdc-1001-will-be-presented-in-a-mini-oral-presentation-at-the-european-society-for-medical-oncology-congress-2023
Bolt Biotherapeutics Announced That Update...
10/16/2023 11:31:53

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION